GLP-1 Medications Linked to Reduced Risk of Serious Infections, Including TB

GLP-1 Drugs and Infection Risk

Recent research indicates that GLP-1 medications, such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), may offer benefits beyond their primary metabolic functions. Two studies have identified a correlation between the use of these drugs and a decreased risk of serious infections, including tuberculosis (TB) and other infections severe enough to necessitate hospital admission.

Tuberculosis Study Findings

One study, published in Nature Communications, specifically investigated the link between GLP-1 use and tuberculosis. Researchers analyzed deidentified medical records, comparing outcomes for individuals with type 2 diabetes taking GLP-1s against those on other common diabetes medications. They found that GLP-1 users had a significantly lower likelihood of being diagnosed with TB over a five-year period.

Hospitalization and Mortality Data

Another study, published in the BMJ, primarily focused on tirzepatide's cardiovascular effects but also noted a reduced incidence of infections leading to hospital stays among tirzepatide users. This study also observed lower overall mortality and reduced death from reported infections in the tirzepatide group. Researchers suggested that the reduction in serious bacterial infections could contribute to the improved survival rates.

Implications for Patient Care

These findings suggest that GLP-1 receptor agonists may provide additional advantages in lowering infection risk, particularly for individuals with type 2 diabetes who are often more susceptible to infections. While further research is needed to confirm these connections, the potential for these drugs to offer protection against infectious diseases could expand their therapeutic utility.